课题基金 / 基金详情

项目摘要

项目成果

KENNETH J. PIENTA的其他基金

相关文献

中文摘要
翻译
前列腺癌是美国癌症死亡的第二大原因。的主要原因
英文摘要
Prostate cancer is the second leading cause of cancer death in the United States. The primary cause of mortality is distant metastatic disease for which androgen deprivation is the initial therapeutic standard. However, virtually all patients treated with androgen deprivation will progress in a predictable and irreversible manner to androgen independence and hormone refractory state. The wide spread use of PSA in the clinic has altered the profile of patients with hormone-refractory prostate cancer. The spectrum now encompasses patients with marked differences in disease burden and symptoms with three main categories of patients that can be identified: Non- metastatic androgen independent disease with rising PSA (i.e. PSA-only disease), rising PSA with stable metastatic disease, and increasing PSA with objective progression. Although historically the role of systemic therapy has been palliative in this stage of the disease, progress in drug development has led to investigating the impact of chemotherapy on survival. Even though it is likely that taxane-based chemotherapy may have an impact on survival, the effect nonetheless is not optimal in that it is complicated by toxicities and has doubtful curative potential. As with any metastatic cancer, the ultimate goals of therapy in this setting are clear: to prolong life, to decrease morbidity, and to increase quality of life. Therefore it is particularly important to investigate alternative novel approaches that stem from observation on the biology of the disease
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Johns Hopkins Physical Sciences Oncology Center
  • 批准号:
    9339630
  • 项目类别:
  • 资助金额:
    $211.84万
  • 财政年份:
    2016
  • 负责人:
    KENNETH J. PIENTA
  • 依托单位:
The Johns Hopkins Physical Sciences Oncology Center
  • 批准号:
    9753736
  • 项目类别:
  • 资助金额:
    $174.51万
  • 财政年份:
    2016
  • 负责人:
    KENNETH J. PIENTA
  • 依托单位:
The JAK2 V617F mutation within B cells and T cells leads to a pro-tumor microenvironment
  • 批准号:
    9903606
  • 项目类别:
  • 资助金额:
    $7.38万
  • 财政年份:
    2016
  • 负责人:
    KENNETH J. PIENTA
  • 依托单位:
The Johns Hopkins Physical Sciences Oncology Center
  • 批准号:
    10016193
  • 项目类别:
  • 资助金额:
    $202.01万
  • 财政年份:
    2016
  • 负责人:
    KENNETH J. PIENTA
  • 依托单位: